![]() |
|
|
Vol. 55, Issue 5, 938-947, May 1999
Program of Molecular Pharmacology, Fred Hutchinson Cancer Research Center, Seattle, Washington (B.J.M., M.A.I., C.M., J.P., C.O., M.M.C.); the Fox Chase Cancer Center, Philadelphia, Pennsylvania (S.W.J.); and Department of Radiation Oncology, University of Washington, Seattle, Washington (J.S.R.)
| |
Summary |
|---|
|
|
|---|
Multicellular contact has been shown to influence the in vitro sensitivity of cells to drug treatment. We investigated the use of macroporous gelatin microcarriers, CultiSpher-G, as a convenient laboratory system for the molecular analysis of this "contact effect". We determined that human A549 cells can be grown in CultiSphers with growth and cell cycle parameters similar to those of monolayers. In addition, cells in CultiSphers express less p27/kip1, an indicator of cell cycle arrest, than equivalent cells in monolayers. When treated with drugs, A549 cells grown in CultiSphers or monolayers accumulate equivalent amounts of platinum-DNA adducts and similar amounts of doxorubicin. Moreover, A549 and KB-3-1 cells in CultiSphers have significantly decreased sensitivity to cis-platinum(II)diammine dichloride (cisplatin), 4-hydroperoxycyclophosphamide, doxorubicin, and paclitaxel (taxol) compared with cells in monolayers when assayed by clonogenic survival. Cisplatin treatment in monolayers or CultiSphers did not result in apoptotic cell death. In contrast, paclitaxel caused a significant amount of sub-G1 DNA, an indicator of apoptosis, which was diminished when cells were grown in CultiSphers compared with monolayers. When grown in CultiSphers, cells with abrogated p53 function (A549/16E6 and NCI-H1299) were less sensitive to cisplatin than the corresponding monolayer cells, indicating that the decrease in sensitivity is p53 independent. Taken together, the data suggest that CultiSpher-G microcarriers are a useful in vitro system to examine the effects of three-dimensional cell contact on drug sensitivity of human tumor cells.
| |
Introduction |
|---|
|
|
|---|
Three-dimensional
intercellular contact in vitro influences the relative sensitivity of
cells to both radiation and drug treatment, a phenomenon generally
known as the "contact effect" (Sutherland et al., 1979
, 1980
;
Rasey, 1984
; Olive and Durand, 1994
; Sakata et al., 1994
). Several
three-dimensional in vitro culture systems have been used to
investigate the effect of intercellular contact on drug sensitivity
(Vescio et al., 1991
; Hoffman, 1993
; Casciari et al., 1997
), with most
studies using multicellular spheroids (Twentyman, 1980
; Sutherland,
1988
; Olive et al., 1993
; St. Croix et al., 1996b
). Although this
"contact effect" has been extensively studied over the last 20 years, the molecular determinants of this effect have just begun to be
identified. This can be attributed, in part, to the difficulty of
separating the effects of cell-cell contact from gradients of drug
penetration, nutrients, oxygen, pH, and cell cycling (Durand, 1990
;
Erlichman and Wu, 1992
; Ramachandran et al., 1995
).
Recently, we characterized the use of CultiSpher-G (HyClone
Laboratories, Logan, UT), macroporous porcine gelatin microcarriers, as
a model cell culture system for drug sensitivity studies. These gelatin
"sponges" with their variegated surface and large internal channels
allow cell growth on the surface and within the bead. Cells growing in
CultiSphers histologically demonstrate significant three-dimensional
contact without central necrosis, lack edge-to-center gradients of
proliferation by [3H]thymidine autoradiography,
and give no indication of a hypoxic fraction on radiation-response
curves (Rasey et al., 1996
). We also documented that in optimal culture
conditions, CultiSphers can be used to produce populations of cells
with extensive cell-cell contact whose cell cycling profiles and
doubling times are similar to those of monolayers of the same cell type
(Rasey et al., 1996
).
To determine whether a "contact effect" might be elicited by growth of tumor cells in CultiSphers, we used four common chemotherapeutic agents eliciting their cytotoxicity through different mechanisms of action: 4-hydroperoxycyclophosphamide (4-HC), the activated analog of cyclophosphamide, paclitaxel (taxol), doxorubicin, and cis-platinum(II)diammine dichloride (cisplatin). Cisplatin has the advantage of producing readily detectable platinum-DNA (Pt-DNA) adducts, and doxorubicin is epifluorescent, characteristics that can be used to determine the equivalency of drug treatments. In the current study, we examined the drug sensitivity of isogenic cells, differing only by growth in CultiSphers or in monolayers on porcine gelatin-coated plastic. We report that growth of the A549 human lung tumor cell line in CultiSphers caused a decreased sensitivity to cisplatin, 4-HC, paclitaxel, and doxorubicin by clonogenic survival assay compared with monolayer controls. This was observed under conditions in which cells in both growth modes had similar cell cycle profiles and accumulated similar amounts of drug. In addition, we report that growth of two other independently derived tumor cell lines (KB-3-1 and NCI-H1299) in CultiSphers decreased their sensitivity to cisplatin. Finally, we report that decreased sensitivity to cisplatin of A549 and NCI-H1299 cells grown in CultiSphers was p53 independent.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials.
All chemicals were purchased from Sigma Chemical
Co. (St. Louis, MO) unless otherwise noted. Culture media was prepared
in-house from powder (Gibco-BRL, Gaithersburg, MD) and media additives were from Gibco-BRL or Atlanta Biologicals (Norcross, GA),
except serum, which was from HyClone. CultiSpher-G gelatin
microcarriers (mean diameter = 220 µm, range 170-270 µm), for
cell culture were obtained from HyClone Laboratories. 4-HC was a gift
of S. Rowley, Fred Hutchinson Cancer Research Center (FHCRC) (Seattle,
WA). Enhanced chemiluminescence Western blotting detection reagents were from Amersham (Arlington Heights, IL). Antisera to human p27 were
a generous gift of Jim Roberts (FHCRC; Polyak et al., 1994
).
Quantitative protein assay was by Bio-Rad (Hercules, CA). Puregene DNA
isolation kits were from Gentra Systems (Minneapolis, MN).
Cell Lines and Culture Conditions.
A549 cells, a p53
wild-type human lung carcinoma cell line (ATCC CCL-185; American Tissue
Culture Collection, Rockville, MD) and transfected derivatives were
maintained in monolayer culture in F/DV medium plus 10% bovine calf
serum (growth medium). A549 derivatives A549/LXSN and A549/16E6 contain
the stably transfected LSXN retroviral vector or vector cDNA encoding
the E6 protein of plus human papilloma virus strain 16, respectively
(Russell et al., 1995
). KB-3-1 cells, a human epithelial carcinoma
derivative (ATCC CCL-17) (Akiyama et al., 1992
) were maintained in
monolayer culture in Dulbecco's modified Eagles medium plus 5% bovine
calf serum. NCI-H1299 cells (ATCC CRL-5803) were maintained in
RPMI-1640 medium with 10% fetal bovine serum. All media were
supplemented with penicillin (100 U/ml) and streptomycin (100 µg/ml)
and 2 mM glutamine. Tissue culture plates were gelatin coated by
treating each dish with 8 ml of 5 mg/ml gelatin (type A, porcine skin) in 0.05 N HCl for 1 h followed by rinsing three times with sterile water. Monolayer cells were plated at 4 × 105 cells per 10 cm2 on
gelatin-coated plates and allowed to grow for 48 h before drug
treatment. CultiSpher-G gelatin microcarriers were seeded by addition
of a single cell suspension (5 × 106 log
phase cells) to 30 ml medium per 0.1 g CultiSphers in a
siliconized spinner flask, agitated for 5 min, and then allowed to
settle undisturbed for 2 h. The spinner was reagitated for an
additional 5 min and allowed to resettle for 2 h. CultiSphers were
removed, washed three times with growth medium to remove unattached
cells, and replaced in the flask with 50 ml growth medium per 0.1 g CultiSphers. The following day an additional 50 ml growth medium was
added per 0.1 g CultiSphers. Each day thereafter, the beads were
allowed to settle briefly, then half the medium was removed and
replaced. CultiSpher occupancy was monitored by staining an aliquot of
beads with 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide, 500 µg/ml in growth medium, at 37°C, for 30 min before
observation. Cell number per bead was quantitated by counting the
number of beads in an aliquot in a gridded Petri dish, recovering and
disaggregating the CultiSphers as described below, and counting cells
in a hemacytometer. CultiSphers were treated with drugs when they
reached 200 to 500 cells/bead, a density at which cells remained in log
phase growth, with no evidence of noncycling cells by flow cytometry,
doubling time, and Ki67 analyses (data not shown). Cells in monolayers and CultiSphers have similar cell cycle profiles under these conditions (Rasey et al., 1996
).
Histology.
For histological analysis, A549 cells were seeded
and grown in CultiSphers to an average of ~1000 cells/bead.
CultiSphers were fixed in neutral buffered formalin, embedded in
paraffin, sectioned and stained with H&E as previously described (Rasey et al., 1996
).
Drug Treatment Conditions. Monolayers or CultiSphers were rinsed once with growth medium to remove detached cells and drug-containing medium was added at 37°C for one hour except as noted. Care was taken to ensure equivalent drug exposure and harvesting conditions with cells grown as monolayers and in CultiSphers. Five milliliters of drug-containing medium was used per 10 cm dish (~1.6 × 106 cells). Larger volumes of CultiSphers were treated in 100- to 250-ml spinner flasks with a similar total drug-medium volume-to-cell ratio. For treatment of small aliquots, washed CultiSphers were placed in drug-containing medium at similar drug-to-cell ratios in 6-cm2 bacteriological dishes, so that cells did not attach, for 1 h with gentle agitation every 10 min. Both monolayer and CultiSpher cells were then harvested using collagenase as per the clonogenic survival assay below. Cisplatin was freshly prepared as a 1 mg/ml stock in PBS, sterile filtered, and appropriate dilutions made in growth medium at 37°C immediately before use. 4-HC stock (100 mg/ml) was freshly prepared in growth medium, sterile filtered, and diluted in medium for immediate use. Doxorubicin was prepared as a 5-mM stock in water and paclitaxel prepared as a 5-mM stock in dimethyl sulfoxide and further diluted in growth medium for immediate use. Cells were then drug treated, washed three to four times in growth medium to remove drug, and then resuspended to original volume with equal parts conditioned and fresh medium. Thereafter, half the medium of dishes or spinners was removed and replaced with fresh growth medium daily.
For cisplatin treatment of cells after release from CultiSphers, cells were dissociated from CultiSphers as described below, then plated at 4 × 106 or 2 × 106 cells per gelatin-coated 15- cm dish for 4 or 24 h, respectively, ensuring a density at treatment of approximately 4 × 106 cells per dish. After release from CultiSphers and replating, the cells in monolayers at 4 and 24 h displayed normal monolayer morphology and could not be removed by agitation alone. Cells in monolayers were then treated with 10 µg/ml cisplatin. For doxorubicin accumulation and clonogenic studies, A549 cells were grown on gelatin-coated dishes (2 × 105 cells/dish followed by 48 h growth) or in CultiSphers (562 cells/bead) and were treated with various doses (clonogenic assay) or 5 µg/ml (110 µM for uptake studies) doxorubicin for 1 h at 37°C in growth medium. After 1 h, cells in CultiSphers were released from beads with collagenase as described below. Cell suspensions were then washed in ice-cold PBS, collected by centrifugation, and kept on ice until analyzed by flow cytometry. To provide the same washing for cells in monolayers and CultiSphers, monolayers were washed two times with PBS, incubated in drug-free growth medium for 1 h, then released from dishes with a 2-min trypsin treatment. Cell suspensions were then washed in ice-cold PBS, collected by centrifugation, and kept on ice until analyzed by flow cytometry. Under these conditions, efflux of drug is minimal in cells, such as A549, that do not express P-glycoprotein (Willingham et al., 1986Clonogenic Survival Assay. To determine cell survival after drug treatment, single cell suspensions from CultiSphers and monolayers were prepared by collagenase. After drug treatment, cells in monolayers or CultiSphers were washed three times with whole medium and once with Hanks' balanced salt solution. Gelatin-containing CultiSphers were digested to release the cells by adding 1 ml of 800 U/ml collagenase in Hanks' balanced salt solution per 1 mg of CultiSphers at 37°C for 1 h, with agitation every 10 min. Known numbers of cells were plated for standard colony-forming assay (3-6 plates per cell dilution, 3-5 dilutions per drug concentration) in 6-cm or 6-well plates. Dilutions with greater than 5 × 104 cells/dish were plated in 10-cm dishes. Surviving fraction was calculated in reference to the plating efficiency of untreated controls (two separate triplicate controls per experiment). Plates were incubated undisturbed for 10 to 12 days. Surviving colonies were stained with 0.5% methylene blue in 50% ethanol, visualized on a Leica StereoZoom 4 dissecting microscope (Leica Inc., Deerfield, IL), and colonies of at least 50 cells on plates containing 50 to 150 colonies were scored as positive.
Cisplatin-DNA Adduct Measurements.
CultiSphers were seeded
in 250-ml spinner flasks, allowed to grow to ~200 to 500 cells/bead,
and monolayers plated as above. Cells were treated with either 10 µg/ml cisplatin for 1 h, 10 µg/ml cisplatin for 4 h, or
40 µg/ml cisplatin for 4 h, washed with PBS, and single cell
suspensions prepared. DNA was prepared using the Puregene DNA isolation
kit. Purity and yield were confirmed by gel electrophoresis and
spectroscopy. DNA was analyzed quantitatively for Pt-DNA adducts by
atomic absorption spectroscopy as previously described (Johnson et al.,
1994
).
Flow Cytometry.
For cell cycle analysis, samples of cell
suspensions were fixed in 50% ethanol, then prepared for flow
cytometric analysis by incubation in PBS containing 0.1% Triton-X100,
25 µg/ml propidium iodide, and 100 µg/ml RNase A for 30 min,
37°C. Cells were analyzed on a Becton Dickinson FACScan with
CELLQuest (Becton Dickinson, San Jose, CA) and MultiCycle AV (Phoenix
Flow Systems, San Diego, CA) analysis software. For doxorubicin
accumulation analysis, cell volume was monitored by forward scatter and
granularity by side scatter, respectively, and a single gate applied to
all samples (under conditions in which over 95% of all cells were
contained within the gate). The doxorubicin fluorescence distribution
was measured in the gated population of cells by excitation at 488 nm
and emission at 585 nm (Luk and Tannock, 1989
). With this methodology the fluorescence of each cell and the distribution of fluorescence of
the population of cells was measured as previously described (McGown et
al., 1983
). For each sample, a statistical marker spanning the single
peak of fluorescence was used to calculate the mean fluorescence
(CELLQuest cytometry analysis software). Greater than 96% of the total
number of gated cells were included in the statistical analysis for
each sample. To estimate the relative uptake of doxorubicin after
1 h of treatment (and 1 h of efflux), the mean fluorescence
in the presence of doxorubicin was normalized to the mean fluorescence
in the absence of doxorubicin.
Immunoblot Analysis.
Cellular protein was prepared from
collagenase-released cells that were washed once with cold PBS, then
lysed on ice for 30 min in 1% Nonidet P-40 in PBS with 10 µg/ml
leupeptin, 10 µg/ml aprotinin, 2 mM 4-(aminoethyl)benzene-sulfonyl
fluoride, 10 mM sodium fluoride, and 5 mM sodium pyrophosphate. Samples
were collected by centrifugation at 8200g for 30 min at
4°C, and the solubilized protein quantitated by the Bio-Rad protein
assay. Samples were stored at
70°C. For immunoblotting, 40 µg
protein/lane was electrophoresed in precast Bio-Rad Mini-Protean II
12% SDS-polyacrylamide gels and electrotransferred to 0.2-µm
nitrocellulose membranes (Schleicher & Schuell, Keene, NH).
Quantitation was confirmed visually with Coomassie blue staining after
polyacrylamide gel electrophoresis. Membranes were blocked overnight in
10 mM Tris-HCl, pH 8; 150 mM NaCl; 0.5% Tween 20 (TBST) and 5% nonfat
dry milk at 4°C. Membranes were then incubated in polyclonal antibody
to p27/kip1 at 1:2000 in TBST with 5% nonfat dry milk for 1 h at
room temperature, followed by 3 × 15 min washes in TBST with 5%
nonfat dry milk at room temperature. Membranes were incubated with goat
anti-rabbit antibody (Santa Cruz Biotechnologies, Santa Cruz, CA) at
1:15,000 for 1 h at room temperature in TBST with 5% nonfat dry
milk, followed by two 15-min washes in TBST with 0.5% dry milk and
three 15-min washes in TBST. The membrane was then incubated with the
chemiluminescence reagent (Amersham) for 1 min, drained, and exposed to
autoradiograph film.
Statistical Evaluation of Data. Averages, S.D.s, and unpaired two-tailed student's t-tests at the 95% confidence interval were performed using Prism 2.0 software (GraphPad Software, San Diego, CA).
| |
Results |
|---|
|
|
|---|
CultiSpher Culture System.
We characterized a multicellular
growth system, macroporous gelatin microcarrier beads called
CultiSpher-G (Nikolai and Hu, 1992
) to study the role that cell
contact and matrix interactions play in determining the response of
cells to chemotherapeutic agents (Rasey et al., 1996
). Figure
1 shows a typical histological section
through a population of CultiSpher beads seeded with A549 cells. Using
the manufacturer's suggested seeding conditions, a range of cell
densities was observed. Some beads were not populated, some beads were
sparsely populated (Fig. 1, A and B; ~100 cells/bead), whereas others
were densely populated (Fig. 1, C and D; ~1000 cells/bead). In the
beads that were populated, cells grew well on both the external and
internal surfaces of the bead. There were areas of single cells or
monolayer-like growth as well as areas of extensive cell-cell contact.
Even at high cell/bead ratios, some beads were not occupied. Therefore,
the number of cells/bead is an average measure of overall occupancy.
Longer growth periods in CultiSphers resulted in an increase in areas
of multicellular contact and decreased single cells (data not shown).
Extensive cell-cell contact within beads occurred while channels were
maintained for drug (Table 1 and see
Results below) and nutrient access (Rasey et al., 1996
).
|
|
|
Analysis of Chemotherapeutic Drug Sensitivity of Cells Grown in
CultiSpher Culture.
Relative sensitivities to clinically relevant
concentrations of drugs were then determined by clonogenic survival
assay (Fig. 3). A549 cells grown as
CultiSphers (Fig. 3A) were much less sensitive to cisplatin compared
with A549 cells grown as monolayers, as indicated by an increased
survival fraction. To determine whether the observed decrease in
cellular drug sensitivity was drug-specific, A549 cells grown as
monolayers and in CultiSphers were exposed to clinically relevant
concentrations of 4-HC or doxorubicin for 1 h or to paclitaxel for
24 h and clonogenic cell survival determined. A549 cells in
CultiSphers were also less sensitive to 4-HC (Fig. 3B), paclitaxel
(Fig. 3C), and doxorubicin (Fig. 3D) compared with A549 monolayers. To
assess whether this phenomenon was cell type-specific, the cisplatin
sensitivities of KB-3-1 cervical cancer cells grown as monolayers and
in CultiSphers were determined. The results demonstrate that KB-3-1
(Fig. 3E) cells were also less sensitive to cisplatin when grown in
CultiSphers than when grown in monolayer culture. Statistical analysis
using Student's t test at 15 µg/ml cisplatin showed
significantly different survival fractions for cells grown as
monolayers versus in CultiSphers (P = .002 for A549
cells in Fig. 3A and P < .001 for KB-3-1 cells in
Fig. 3E). Further analysis by t test showed significant
differences in survival fractions of A549 monolayers versus CultiSphers
at 200 µg/ml 4-HC (P < .0001; Fig. 3B), 100 nM
paclitaxel (P < .0001; Fig. 3C), and at 1 µM
doxorubicin (P = .0009; Fig. 3D).
|
Analysis of Doxorubicin Accumulation and Cisplatin DNA Adduct
Formation in A549 Cells Grown as Monolayers and in CultiSphers.
The decreased sensitivity of cells in CultiSphers might be explained by
decreased drug accumulation or by lower drug concentration in a subset
of cells. This possibility was examined using two methods. First, flow
cytometry was used to determine doxorubicin accumulation and
distribution within the cell population of monolayer and CultiSpher
A549 cultures. Doxorubicin was chosen because it has been shown that
treatment of cells grown as multicellular spheroids results in large
doxorubicin concentration gradients, and thus it represents a stringent
test of drug accumulation and distribution (McGown et al., 1983
; Sakata
et al., 1994
). Cells were incubated with 5 µg/ml doxorubicin for
1 h at 37°C, released by trypsin or collagenase treatment, and
washed free of drug using ice-cold growth medium to prevent doxorubicin
diffusion. Doxorubicin epifluorescence was measured in duplicate
samples by flow cytometry (McGown et al., 1983
; Luk and Tannock, 1989
).
The flow cytometry data (Fig. 4) shows
that when normalized to autofluorescence the shift in mean fluorescence
following doxorubicin treatment was about 2-fold greater for cells in
CultiSphers compared with cells in monolayer. These data suggest that
cells in CultiSphers accumulated more, not less, doxorubicin than cells
in monolayers in this experiment. In repeated experiments, cells in
CultiSphers never had lower mean fluorescence than cells in monolayers,
indicating that cells in CultiSphers and monolayers had at least equal
doxorubicin uptake. Furthermore, the shapes of the histograms for the
accumulation of doxorubicin were very similar (Fig. 4), suggesting that
the distribution of doxorubicin, on a per cell basis, was similar in
cells treated in monolayers and in CultiSphers.
|
Role of p53 in Response to Cisplatin Treatment in Cells Grown in
CultiSphers and Monolayers.
The decreased sensitivity of response
to DNA damage by cisplatin of cells grown in CultiSphers (Fig. 3)
suggested that levels of DNA damage recognition and response proteins,
such as p53, might be different in cells in the two growth conditions.
To examine this possibility, cell lines that differed in p53 expression
were used. Derivatives of the parental A549 human lung tumor cell line, A549/LXSN, and A549/16E6, as well as the p53 null line NCI-H1299, were
grown as monolayers and CultiSphers and then treated with cisplatin.
A549/LXSN cells, containing an empty retroviral vector, have similar,
low basal levels of p53 expression when grown both as monolayers and in
CultiSphers (data not shown). A549/16E6 cells contain a retroviral
vector expressing the human papilloma virus strain 16 E6 protein, which
abrogates wild-type p53 function by facilitating its degradation via
the ubiquitin pathway (Scheffner et al., 1990
; Butz et al., 1995
; Rolfe
et al., 1995
). The absence of p53 protein in the A549/16E6 cell line
was confirmed by Western blot analysis (data not shown) before the
clonogenic experiments described below.
|
Cell Cycle Response to Drug-Induced Damage in Cells Grown in
CultiSphers and Monolayers.
Cisplatin treatment induces
G2/M cell cycle arrest (Sorenson and Eastman,
1988
; Rolfe et al., 1995
) in many, but not all, cell types containing
wild-type p53 (Sorenson et al., 1990
; Fan et al., 1994
, 1995
; Fujiwara
et al., 1994
; Hawkins et al., 1996
; Kawasaki et al., 1996
). To
determine whether growth conditions altered this response, asynchronous
cultures of A549/LXSN and KB-3-1 cells grown as monolayers and in
CultiSphers were treated with 10 µg/ml cisplatin for 1 h,
washed, allowed to recover in situ, and then serially harvested for
flow cytometry analysis for up to 120 h after treatment. Aggregate
data from 10 separate cell cycle experiments indicate that S phase
fractions for monolayers (31.77 ± 18.11%) and CultiSphers
(22.89 ± 15.27%) are not statistically significant from each
other using Student's t test (P = .71). This suggests that cell cycle profiles at the time of drug treatment for monolayers and CultiSphers are not significantly different. As
shown in Fig. 6, by 48 h after
treatment both A549/LXSN monolayers (Fig. 6A) and KB-3-1 monolayers
(Fig. 6B) exhibit a G2 arrest that continues
until at least 96 to 120 h post-treatment. However, a prolonged
G2/M arrest of A549 cells grown as monolayers
following cisplatin treatment was not observed in every experiment, and did not correlate well with cell survival (data not shown). When either
A549/LXSN or KB-3-1 cells were grown in CultiSphers and treated with
cisplatin, a portion of the cells appear to remain in
G1. Between 72 to 120 h after cisplatin
treatment the proportion of cells in G1 increased
relative to 48 h, suggesting that some cells progress past
G2/M and arrest in G1. In
addition, no sub-G1 DNA content, an indicator of
apoptosis, was observed following treatment of A549 or KB-3-1 cells
with cisplatin. It should be further noted that neither A549 nor KB-3-1
cells respond to cisplatin, at the doses used in these studies, by
undergoing classical apoptosis (no sub-G1 DNA
content, minimal poly(ADP)ribose polymerase cleavage, minimal DNA
laddering, minimal annexin V binding (M. Ihnat and M.M. Cornwell
unpublished observations).
|
| |
Discussion |
|---|
|
|
|---|
These studies suggest that the growth of human cancer cell lines
in macroporous, microcarrier beads can alter their response to cancer
chemotherapeutic agents compared with growth as dispersed monolayer
culture. We have previously demonstrated that cells in CultiSphers
exhibit substantial three-dimensional contact without central necrosis
and lack an edge-to-center gradient of proliferation or evidence of a
hypoxic fraction (Rasey et al., 1996
).
In the present work, we demonstrate that cells in CultiSphers can be
grown with similar cell cycle profiles as monolayers under conditions
in which similarly low levels of the cell cycle inhibitor p27/kip1,
which causes cell cycle arrest, are expressed. In our studies, cells
grown as monolayers lacking p53 (A549/16E6, NCI-H1299) are less
sensitive to cisplatin treatment when compared with similar cells with
an intact p53 (A549, A549/LSXN). Cells lacking p53 function have been
shown to have increased (Hawkins et al., 1996
) as well as decreased
(Piovesan et al., 1998
) sensitivity to cisplatin, thus the role of p53
in drug resistance has yet to be fully understood. Furthermore, three
human epithelial-derived cancer cell lines with differing p53 status
(wild-type, E6-expressing, and null) all demonstrate
significantly altered drug responses in CultiSpher compared with
monolayer culture. These data suggest that the decreased cisplatin
sensitivity of cells in CultiSphers is p53-independent. In addition,
altered responses to drug treatment are observed under culture
conditions that produce similar growth and drug distribution.
Determining equivalent drug uptake in cells grown in monolayers and
CultiSphers is crucial, because it is known that multicellular growth
can alter the total accumulation of drug per cell by causing drug
gradients (Durand, 1990
; Erlichman and Wu, 1992
; Johnson et al., 1994
;
Ramachandran et al., 1995
). We use two approaches to document that drug
distribution is comparable in cells grown in monolayers and
CultiSphers. First, we demonstrate using doxorubicin epifluorescence
that cells in monolayers and CultiSphers have similar drug distribution
histograms. This indicates that, unlike cells grown in spheroids
(Sutherland et al., 1979
; Sakata et al., 1994
), all the cells in the
CultiSphers accumulate doxorubicin to a similar degree and to at least
an amount comparable with cells grown as monolayers. Second, we
demonstrate that cells in monolayers and CultiSphers form similar
amounts of Pt-DNA adducts as monolayer cultures. Thus, differences in
Pt-adduct formation are not likely to account for the observed
differences in drug sensitivity. These data also suggest that cellular
mechanisms that alter postuptake cisplatin metabolism (such as altered
glutathione levels and multidrug resistance protein pump
activity) do not account for the decreased drug sensitivity of cells in CultiSphers.
We report that cells grown in CultiSphers at the time of treatment with
chemotherapeutic agents express very little p27/kip1, a mediator of
cell cycle arrest (Polyak et al., 1994
). This contrasts with studies
using multicellular spheroids as a model, in which increased p27
expression has been correlated with decreased drug sensitivity (St.
Croix et al., 1996a
). Thus we believe that the decreased drug
sensitivity observed with cells grown in CultiSphers is not due to an
arrested population of cells as a result of growth in three dimensions,
as is the case with cells grown as multicellular spheroids.
We also did not find an obvious correlation between cell cycle response and clonogenic survival in monolayer versus CultiSpher cultures after cisplatin treatment. Although the majority of A549 cells and all KB-3-1 monolayer cells enter a prolonged G2/M arrest by 48 h after 10 µg/ml cisplatin treatment, A549 cells in monolayers do not always remain in G2/M at longer time points following treatment. However, when A549 or KB-3-1 cells are grown in CultiSphers before cisplatin treatment, in every experiment a portion of both cells fail to exit G1, while some cells progress past G2/M. Thus, with asynchronous A549 cultures, a clear correlation cannot be made between decreased sensitivity of cells in CultiSphers and cell cycle response following cisplatin treatment. Experiments using synchronous cell populations to further investigate the altered cell cycle response of cells in CultiSphers are in progress.
Through immunoblot analysis of proteins associated with apoptosis and
markers of apoptotic cell death, we found that 10 µg/ml cisplatin
treatment for 1 h does not kill A549 cells through classical apoptotic pathways (data not shown). It was further observed that many
A549 cells remain attached to cell culture dishes following 10 µg/ml
cisplatin treatment but do not proliferate to form colonies (data not
shown). To confirm that cisplatin-treated cells from both growth modes
were viable post-treatment, equal numbers of cells from A549 monolayers
and CultiSphers were plated after a 1 h cisplatin treatment and
then assayed for viability using the 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxy
methyoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) cell
dehydrogenase assay or by trypan blue staining. At 48 and 72 h
post-treatment, no difference in MTS dehydrogenase activity or trypan
blue dye exclusion was observed following treatment of cells in
monolayers and CultiSphers (data not shown). Thus, we speculate that
growth of cells in CultiSphers increases the ability of
cisplatin-treated cells to proliferate rather than induces the cells to
die. If correct, the effect of cisplatin on proliferation rather than
viability may account for the observations made by Frankel et al.
(1997)
in which no difference in cisplatin sensitivity between cells
grown as monolayers and multicellular spheroids was observed. In that
study the sensitivity of cisplatin-treated cells was measured by MTS
and [3H]thymidine incorporation, not by
clonogenic cell survival.
The sensitivities to chemotherapeutic drugs that form DNA adducts (cisplatin and 4-HC), intercalate into DNA, and alter cellular membranes (doxorubicin), as well as to an agent that does not directly adduct DNA (paclitaxel), are all decreased by multicellular growth in CultiSphers. Thus, it is possible that the decreased drug sensitivities of cells grown in CultiSphers relative to monolayers are independent of drug mechanism of action. The decreased sensitivity to paclitaxel of cells grown in CultiSphers compared with monolayers suggests that this phenotype is not solely related to augmented DNA repair of drug-induced lesions. In addition, the observation that paclitaxel induces sub-G1 content (an indicator of apoptosis) in A549 monolayers and CultiSphers, whereas cisplatin does not, also suggests that decreased drug sensitivity of cells grown in CultiSphers is not due to a defect in the apoptotic pathway, but rather to a qualitative change in apoptotic response.
Although it is probable that there are distinct drug-specific pathways
within the cellular damage response signaling network, we speculate
that a set of common events occurring before drug treatment, dependent
on multicellular growth, alters the cellular damage response through
specific signaling pathways. Data suggesting that the CultiSpher
resistance phenotype is reversed or lost after replating cells for
24 h, but not for 4 h, before drug treatment supports our
speculation that growth conditions before drug exposure determine the
clonogenic survival of cells. Our current working hypothesis is that
multicellular growth of cells in CultiSphers activates survival factor
signaling networks (Evan et al., 1995
), which in turn inhibit
drug-induced cell death signals and promote cell proliferation.
Our aim was to develop a model in vitro culture system that is similar to three-dimensional cellular contact in vivo while retaining the advantages of homogeneous, comparable, easily manipulated cell populations for molecular analysis. We demonstrated that extensive cell-cell contact exists in CultiSphers in a cell population that is similar to dispersed monolayers in several important parameters, especially comparable cell cycle transit time and drug uptake. We are currently investigating whether growth in CultiSphers alters drug response by facilitating cell-cell interactions, and thereby the formation of gap junctions, extracellular matrix deposition, and ligand-receptor interaction, etc., or whether changes in drug response are independent of cell-cell contact. In summary, this work demonstrates that the growth of cells in CultiSphers provides a relatively simple and useful model system with advantages over monolayer culture to advance the molecular characterization of cell contact-induced drug resistance.
| |
Acknowledgments |
|---|
We thank members of the Cornwell laboratory, especially Denise Simoneaux, as well Susan Kane for providing helpful comments on this manuscript.
| |
Footnotes |
|---|
Received August 27, 1998; Accepted February 12, 1999
1 These authors contributed equally to this manuscript.
2 Current address: Childrens Center for Cancer and Blood Diseases, Childrens Hospital Los Angeles Research Institute, MS 57, 4650 Sunset Blvd., Los Angeles, CA 90027.
This work was supported by Public Health Service Grant RO1 CA63419 (to M.M. Cornwell). J. Rasey was supported by National Institutes of Health (NIH) Grant R37 CA34570. B. Maurer was supported by NIH training Grant T32 CA 09351. M. Ihnat was supported by NIH training Grant T32 DK07742-02 through the University of Washington School of Medicine, Department of Gastroenterology.
Send reprint requests to: Dr. Marilyn M. Cornwell, Fred Hutchinson Cancer Center, Mail Stop D2-100, 1100 Fairview Ave. N., Seattle, WA 98109. E-mail: mcornwel{at}fhcrc.org
| |
Abbreviations |
|---|
4-HC, 4-hydroperoxycyclophosphamide; cisplatin, cis-platinum(II)diammine dichloride; Pt-DNA, platinum-DNA; TBST, 10 mM Tris-HCl, pH 8, 150 mM NaCl, 0.5% Tween 20, p27, p27/kip1; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy methyoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium.
| |
References |
|---|
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||